Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting
C Gisselbrecht - British journal of haematology, 2008 - Wiley Online Library
The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy was a milestone in the development of front‐line therapy for …
prednisone) chemotherapy was a milestone in the development of front‐line therapy for …
Second-line treatment paradigms for diffuse large B-cell lymphomas
C Thieblemont, C Gisselbrecht - Current oncology reports, 2009 - Springer
Despite recent major advances in treating diffuse large B-cell lymphoma with dose-intense
regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant …
regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant …
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma
J Lignon, D Sibon, I Madelaine, P Brice… - … Myeloma and Leukemia, 2010 - Elsevier
Background Salvage therapy for patients with refractory/relapsed B-cell non-Hodgkin
lymphoma (NHL) is based on polychemotherapy, followed by high-dose therapy and …
lymphoma (NHL) is based on polychemotherapy, followed by high-dose therapy and …
Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients
S Aydin, U Dührsen, H Nückel - Annals of hematology, 2007 - Springer
The anti-CD20 antibody rituximab improves the results of first-line therapy in aggressive non-
Hodgkin's lymphoma (NHL) of B cell lineage. The purpose of this retrospective study was to …
Hodgkin's lymphoma (NHL) of B cell lineage. The purpose of this retrospective study was to …
Rituximab (Rituxan®)
A Böhnke, M Wenger - Handbook of Therapeutic Antibodies, 2014 - Wiley Online Library
Summary Rituximab (MabThera, Rituxan) is a chimeric (mouse/human) monoclonal
antibody against CD20. As CD20 is expressed exclusively on malignant or normal B‐cells …
antibody against CD20. As CD20 is expressed exclusively on malignant or normal B‐cells …
Rituximab (Rituxan)
M Wenger - Handbook of Therapeutic Antibodies, 2007 - Wiley Online Library
Rituximab (MabThera, F. Hoffmann La-Roche; Rituxan, Genentech and Biogen Idec)–a
chimeric monoclonal antibody (mAb) produced by recombinant technology–entered clinical …
chimeric monoclonal antibody (mAb) produced by recombinant technology–entered clinical …